Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial

BACKGROUND: Major depressive disorder (MDD) is a prevalent and disabling disorder that can lead to heavy individual, familial, and societal burdens. Although pharmaceutical interventions still play an essential role in therapeutic measures, limitations, including effects that are delayed for weeks,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Trials
Auteurs principaux: Zhou, Jingjing, Wang, Weiwei, Yang, Jian, Zhu, Xuequan, Feng, Lei, Xiao, Le, Wang, Gang
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6327471/
https://ncbi.nlm.nih.gov/pubmed/30626409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-3132-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires